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 Polycystic ovarium syndrome (PCOS), the most common endocrine 
disorders in women of reproductive age, characterized by menstrual 
disorders (amenorrhea/oligomenorrhea), hirsutism, the appearance of acne, 
alopecia and the results of biochemical tests that show increased androgens 
(testosterone). Increased serum luteinizing hormone (LH) and follicle 
stimulating hormone (FSH) serve as diagnostic tests for PCOS over  
the years, but from several research results obtained inconsistent results that 
need further research. The purpose of this study is to analyze the hormonal 
profile and characteristics of polycystic ovary syndrome (PCOS) in Madura. 
Case-control study conducted in March-August 2019 in the Madura tribe. 
There were 32 subjects with PCOS and 32 healthy women participated in this 
study. Hormonal examination was using a serum and followed by enzyme-
linked immune sorbent assay (ELISA kit). Levels Follicle-stimulating 
hormone (FSH) average was 8.74 and SHBGs were 10.02 lower in PCOS 
patients and LH levels were higher in PCOS patients; ratio LH/FSH was 
0.76. The results of the Madurese study showed that levels of FSH, LH, 
weight significantly related to PCOS sex hormone binding globulin (SHBG), 
however body mass index (BMI) levels were not related to PCOS. 
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1. INTRODUCTION  
Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women of 
reproductive age, characterized by menstrual disorders (amenorrhea/oligomenorrhea), hirsutism, emergence of 
polycystic ovary syndrome (PCOS), one of the most common endocrine disorders in women of reproductive 
age, characterized by menstrual disorders (amenorrhea/oligomenorrhea), hirsutism, emergence of polycystic 
ovary syndrome (PCOS) the results of biochemical examination showed that androgens (testosterone) were 
increased [1-3]. Long-term effects of PCOS usually occur with infertility, insulin resistance, increased risk of 
diabetes and cardiovascular disease [4, 5]. El Hayek said the prevalence of PCOS is around 4% to 10% of 
women worldwide [1].  
There are three criteria for the diagnosis of PCOS, namely the national institutes of health (NIH) 
Criteria, the criteria for androgen excess and polycystic ovarian syndrome society (AE-PCOS), and Rotterdam 
criteria. The Rotterdam Criteria is a consensus that resulted from a conference organized by the European 
society for human reproduction and embryology/the American society for reproductive medicine 
(ESHRE/ASRM) in 2003. A diagnosis of PCOS is established by the Rotterdam criteria if two of the following 
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three criteria are found, namely dysfunction ovaries, hyperandrogenic manifestations, and polycystic ovary 
morphological features. The Rotterdam Criteria are the criteria used for handling infertility [6, 7]. 
 In PCOS patients there is an increase in the hormone's LH and FSH as much as 70% or 2-3 times that 
of normal women. Increased serum LH and FSH serve as diagnostic tests for PCOS over the years,  
but from several research results obtained inconsistent results. Several studies reported serum levels LH basal 
inversely correlated with body mass index (BMI) in PCOS patients, who did not find an association between 
BMI and levels LH in PCOS patients [8]. An increase in LH occurs in thin and normal women whereas  
a decrease in LH is even normal in obese women [9]. So that early detection of PCOS is needed more 
consistently and earlier because early detection of PCOS determines the success of therapy. 
Reproductive hormonal disorders are often found in PCOS. Increased function of luteinizing hormone 
(LH) is an important factor in the pathophysiology of PCOS that causes ovarian theca cells to produce excess 
androgen hormones so that there is a state of hyperandrogenism. The state of hyperandrogenism causes  
a disturbance in the development of ovarian follicles so that the follicular maturation process is inhibited.  
This condition causes the follicle growth to stop at a diameter of 2-9 mm and produces a polycystic ovary 
appearance [10]. Research on examining hormonal levels and characteristics in PCOS patients has never been 
done based on ethnicity. This study is to analyze the profile of hormonal levels and characteristics of Polycystic 
Ovary Syndrome in Madura. 
 
 
2.  RESEARCH METHOD  
This study used case-control, where there are two groups, PCOS cases and healthy women control 
with a total sample of 64. The criteria of a control group of native Madurese women, aged 20-40 years and 
already married, currently were not using hormonal contraception three months before, did not have diseases 
such as sugar, liver and kidney levels, while the case group, native Madurese women, aged 20-40 years and 
married, did not have diabetes, liver and kidney disease, women with first pregnancy program. Sampling was 
carried out during the 3-5 days of menstruation and morning. Every patient besides blood drawn weight and 
height examination to measure BMI and continued blood drawn to take serum followed by an examination 
their levels of the hormone FSH, LH and SHBG on all respondents by using the ELISA kit.  
FSH uses ELISA kit 180670, sex hormone binding globulin (SHBG), enzyme-linked immune sorbent assay 
(ELISA) kit 96T, and LH ELISA kit 4040. The examination material is derived from venous blood of 
research subjects obtained through a phlebotomy procedure, and then the examination material is left for  
30 minutes until a clot is formed. The test material is centrifuged at a speed of 1,000 g for 20 minutes until  
the serum is formed. Afterward, serum is stored at -800C until the required sample size met 64 respondents. 
Previously all respondents were screened for serum glutamic oxaloacetic transaminase (SGOT), blood urea 
nitrogen (BUN), creatinine and blood sugar to ensure that the respondents were in good conditions and will 
continued for further examination. But if there were any respondents did not meet the criteria then they will 
be excluded.  
The study protocol was approved by Ngudia Husada Madura Institute of Health (STIKes) and 
Eligible Ethics No. 0034/KEPK-NHM/EC/II/2019. To find out the differences between the case and control 
groups both respondent characteristics and hormonal levels we were using the Mann-Withney statistical test. 
To find out which variables have significant effect on PCOS, we were using logistic regression with  
a significance level of 0.05. Statistical analysis was using the Statistical Package for the Social Sciences 
(SPSS) version 21.0 for windows. 
 
 
3.  RESULTS AND DISCUSSION 
3.1  Distribution of clinical symptoms in study subjects 
Table 1 shows distribution of clinical symptoms among respondent of secondary amenorrhea, 
hirsutism, acne great sound, alopecia. Based on Table 1 it is found that most of the study subjects in PCOS 
patients have 2-3 clinical symptoms, and most often clinical symptoms that appear are amenorrhoea, 
hirsutism and the appearance of acne.  
 
 
Table 1. Distribution of clinical symptoms in study subjects 
Variable n=% 
Secondary Amenorrhea 30 (100) 
Hirsutism 19 (63.33) 
Acne 18 (60) 
Great sound 2 (6.7) 
Alopecia 0 (0) 
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Table 2 shows result of respondent age, weight, height, BMI and LH/FSH. Based on Table 2, it was 
found that the average age of PCOS was 30.57 years and control was 25.27 years, BMI of research subjects 
was an average of 26.06 and controls 22.55 then weight research subjects were average mean 63.56 and 
control 53.07. There was a difference in weight, BMI ratio FSH and LH with p< 0.05, and there was no 
difference for height because p< 0.05. Due to the data were not normally distributed p< 0.05 then was using 
the statistical test Mann-Withney. Table 3 shows the logistic regression test.  
 
 
Table 2. Result of research subjects 
Characteristics of PCOS Control p-value 
Age 30.57 ± 5.37 25.27 ± 4.93 0.000 
Weight 63.56 ± 13.97 53.07 ± 5.99 0.003 
Height 155.7 ± 6.47 154.3 ± 5.04 0.571 
BMI  26.06 ± 4.63 22.55 ± 2.16 0.003 
LH/FSH 0.76 ± 0.50 0.43 ± 0.20 0.009 
Value of normality Shapiro Wilk   0.041 
 
 
Table 3. Logistic regression test result  
Variabel ß Signifikan Exp(ß) Lower Upper 
Age 0.235 0.002* 1.265 1.089 1.471 
Weight 0.095 0.022* 1.100 1.014 1.193 
Height -0.235 0.752 0.791 0.184 3.397 
BMI  -0.304 0.343 0.738 0.394 1.383 
FSH (IU/I) -0.254 0.014* 0.776 0.634 0.950 
LH (IU/I) 0.384 0.018* 1.468 1.069 2.015 
SHBG (IU/I) -0.002 0.259 0.998 0.994 1.002 
 
 
 Results of the current research show that age in the PCOS group were on average 30 years old and  
in the control group 25 years old, seen from the age in the range of healthy reproductive age. PCOS also often 
occurred in adolescents, this is in accordance with research conducted by Fazleen, that in adolescents there were 
many metabolic syndromes associated with PCOS. However, several studies explained that many PCOS 
identified/diagnosed at reproductive age [11]. At the reproductive age, the quality of eggs should be in good 
condition, but because of obesity and imbalance of the hormones FSH and LH, it will affect the quality 
 of the eggs to shrink, which will result in PCOS.  
Based on research conducted by Pinola revealed that at age >39 years, BMI and waist circumference 
were higher in the hyper androgenic PCOS group than in the normal androgen PCOS group [12]. This is in line 
with research conducted in the Madura tribe that the PCOS group had a BMI in the obesity category at the age of 
>30 years. The results of this study also showed in the PCOS group, BMI were in the 50% obesity category and 
50% normal, while in the BMI control group, there were in the normal categories, signs, and symptoms of PCOS 
one of which is irregular menstruation due to obesity, this is in accordance with the Mahedia 2018 study, said that 
women who are obese will increase the occurrence of irregular menstruation causing infertility [13, 14]. 
 This parallel study conducted by Jamil, revealed that BMI was significant in the Aotipers (Oligo 
anovulation, hyper androgenic and PCOS) [14]. Research conducted in Norway, 2001 that BMI did not 
correlate with insulin resistance, but did affect the decrease in egg cell quality and increase in FSH [15].  
The study also revealed that 50% of PCOS were not obese [16]. Another study conducted by Diamanti,  
revealed that 40-60% of PCOS women are overweight or obese, and this is widely understood and accepted 
then obesity is also associated with health risks [17, 18]. 
 The results of this study were based on the characteristics of PCOS patients and healthy women found, 
weight, BMI had a significant relationship, weight and BMI in PCOS patients were higher than in the control 
group, and this was consistent with Bassiuny, research that BMI was significantly higher in the PCOS  
group [19]. This study is also in line with Mukherjee, 2009 said that BMI and weight were significantly higher 
than controls [20]. A study conducted by Martinez, 2007 said obesity and overweight are clinical manifestations 
of PCOS, especially obesity that occurs in the abdominal area; even 50% of women who are obese  
or overweight will develop PCOS [21].  
 Based on those research reports, it can be seen that BMI was a risk factor for PCOS [22].  
Excess deposits in the abdomen, especially in the visceral part are indicative of an increase in androgens  
in the ovary that triggers PCOS [23]. Moran and Teede, reported that abdominal adipocytes are a risk factor for 
metabolic disorders in PCOS patients. Hyperandrogenism and insulin resistance can affect metabolic 
abnormalities either directly or indirectly in women who are obese especially in the abdominal region [24]. 
Research conducted on Indian women with a sample of 63 obese PCOS patients revealed that the characteristics 
of anthropometry especially BMI and pelvic circumference were the most important parameters and were 
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highly related to the incidence of PCOS compared to insulin resistance in obese PCOS patients, so it was very 
important for treatment premature obesity to prevent dyslipidemia in the future [25]. It was reported that LH 
levels, ratio LH/FSH was higher in the PCOS group than in the normal group, whereas SHBG levels found to 
be lower in the PCOS group than in the normal group [22]. When puberty occurs physiologically there is an 
increase of insulin in the body there will be a decrease SHBG levels which will increase androgen levels  
in the ovary by stimulating the ovaries directly, in women with PCOS, physiologically hyperinsulinemia has 
occurred in adolescence and triggers hyper androgenic and anovulation, teenagers who tend to insulin resistance 
and being overweight are risk factors for PCOS [26]. 
This study is in line with research in the Madura tribe which found higher LH levels and lower SHBG 
levels in the PCOS group compared to the control group. While the levels of FSH, LH, and SHBG there was no 
difference between the PCOS group and the normal group. And the results of the ratio LH/FSH found there were 
significant differences between cases and controls in the Madura tribe. The current diagnosis of PCOS can be seen 
from the results of the LH/FSH ratio, if the ratio LH/FSH >2 then the possibility of a diagnosis of PCOS is greater. 
Judging from the relationship test, FSH levels and LH there is a significant relationship between PCOS. In women 
of reproductive age, FSH is an important hormone needed for follicular development, oocyte maturation, and 
regulation of steroidogenesis in the ovaries. Research conducted on adolescents in Turkey experiencing PCOS 
found that BMI, waist circumference, LH levels and ratios LH/FSH was higher in the PCOS than in the control 
group, whereas FSH and SHBG levels were lower in PCOS than in the PCOP group control [23]. The same study 
was also carried out in Turkey in adolescents who experience hirsutism in PCOS, reporting that the ratio LH/FSH 
is higher and SHBG levels are lower and really significant in the incidence of PCOS [27].  
 One of the common clinical manifestations in PCOS patients is an assessment of the difference  
in the range between LH and FSH levels through the ratio LH/FSH when >2 is said to be PCOS [28]. In women 
with PCOS, an increase in LH levels will secrete excess androgens in the ovaries, and FSH levels can stimulate 
cells in the ovary to convert excess androgens into estrogen. In certain women, excess levels LH can not only cause 
high androgen levels from theca and ovarian cells but can also increase estrogen from other cells in the ovary [29]. 
Previous research reported that there was no significant difference between the obese and non-obese groups in 
PCOS patients and from the results of FSH, LH levels and also ratio of LH/FSH [30]. This is in line with this study 
that there was no significant difference between the case and control groups, but from the logistic regression 
results, there is a significant relationship between LH and FSH with the incidence of PCOS.  
A high percentage (55-75%) of women with PCOS have high ratios of LH/FSH probably due to higher 
levels of LH than decreased production of FSH. Stimulation GnRH causes the production of LH excessive in 
women. This condition can be determined by the highest frequency or amplitude of GnRH. On the other hand, 
PCOS patients have higher and lower concentrations LH and FSH than normal women [26].  
Research conducted by Jamil revealed that women with D-suppressors (Oligo anovulation and PCOS) showed 
LH/FSH significantly lower ratios, testosterone levels, and androgen levels. FSH and SHBG levels were higher 
than those with an Oligo anovulation, hyperandrogenic and oscillator PCOS [14]. This study is not in line with 
research conducted in Madura that found lower FSH and SHBG levels as well as higher LH levels in PCOS group. 
Research in Madura was in line with Turhan's 1999 studied of 32 PCOS patients and controls of 25 healthy women 
revealed that LH levels were higher and SHBG and FSH levels were lower in PCOS [30]. The path analysis found 
that hormone level is very significantly related to PCOS are FSH levels and LH levels. This is in line with research 
conducted by Turhan revealed that the combination of both hormone FSH levels and LH can be used to predict of 
PCOS, especially in the ratio of FSH/LH [30]. 
 
  
4.  CONCLUSION 
Most of the Madurese tribe in Indonesia, age and weight contributed to BMI. Waist circumference 
was higher in the hyper androgenic PCOS group than in the normal androgen PCOS group. FSH levels and 
LH levels were significantly related PCOS. The combination of both hormone FSH levels and LH can be 
used to predict of PCOS, especially in the ratio of FSH/LH. Among reproductive age women, FSH is an 
important hormone needed for follicular development, oocyte maturation, and regulation of steroidogenesis 
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